Brand Names of Pefloxacin in Kenya
Pefaxin®, Emil Pharmaceutical Industries Private Limited
Peflobid®, Cadila pharm
Pefloma, ®Plethico Pharmaceuticals Ltd.
Pelox®, Wockhardt Ltd
Perti®, Dr Reddy
Pefloxacin is a quinolone antibiotic used to treat bacterial infections
PEFLOXACIN MODE OF ACTION
The bactericidal action of pefloxacin results from interference with the activity of the bacterial enzymes DNA gyrase and topoisomerase IV, which are needed for the transcription and replication of bacterial DNA. DNA gyrase appears to be the primary quinolone target for gram-negative bacteria. Topoisomerase IV appears to be the preferential target in gram-positive organisms. Interference with these two topoisomerases results in strand breakage of the bacterial chromosome, supercoiling, and resealing. As a result DNA replication and transcription is inhibited.
INDICATIONS
This medicine is used for the treatment of uncomplicated gonococcal urethritis in males and for gram-negative-bacterial infections in the gastrointestinal system and the genitourinary tract.
These may include:
- Uncomplicated gonococcal urethritis in males.
- Bacterial infections in the gastrointestinal system.
- Genitourinary tract infections.
- Gonorrhoea. however this indication is no longer effective due to bacterial resistance.
Pefloxacin is a medication belonging to the antibiotic group known as fluoroquinolones.
DOSAGE AND ADMINISTRATION
Oral: Adults – 400 mg bid 7 to 10 days taken along with food.
IV Infusion: Adults – 400mg in 100ml of 5% dextrose slow infusion over 1 hr bid.
DRUG INTERACTIONS
Antacids interfere with absorption.
Increased anticoagulant effect of warfarin.
Theophylline kinetics may be altered by concomitant use of pefloxacin.
The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Amiodarone.
The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Amisulpride.
Rifampicin reduces serum levels.
ADVERSE DRUG REACTIONS
Allergic Reactions ( call emergency if you have these signs) : hives , difficulty breathing, swelling of your face, lips, tongue, or throat
Gastric pain
Nausea
Vomiting
Allergic skin reactions
Photosensitivity
Muscular pain
Headache
Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome.
Reporting of suspected adverse reactions:
The PPB Department of Pharmacovigilance was set up with a vision to develop, implement and continuously upgrade an appropriate system for detecting, reporting, and monitoring adverse drug reactions (ADRs) and other relevant problems with medicines in Kenya. The department strives to ensure the safety and efficacy of pharmaceutical products in Kenya.
Reporting suspected adverse reactions after authorization of the medicinal product are important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals/ Patients are encouraged to report any suspected adverse reactions via Pharmacovigilance Yellow Form, pv@pharmacyboardkenya.org or clicking below button:
Pefloxacin in Kenya
Pefloxacin in Kenya
Pefloxacin in Kenya
Pefloxacin in Kenya
Clinical | Pharmacokinetic data
Pregnancy Category: This medicine is not recommended for use in pregnant women unless absolutely necessary.
Routes of Administration: Oral , Infussion (IV)
Bioavailability: 100%
Protein Binding: 20–30%
Metabolosim: Hepatic
Onset of Action: N/A
Elimination Half life: 8.6 hours
Excretion: Mostly renal, also biliary
Legal Status | Dosage forms & Strengths
Prescription Category:
Prescription only Medicine (POM) , â„ž-only
Narcotic Drugs and Psychotropic Substances (Control ) Act Schedule:
This drug is not a controlled substance under Narcotic Drugs and Psychotropic Substances (Control ) Act
Dosage Forms | Strengths:
Drug Indentifiers:
| CAS Number | |
|---|---|
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | |
Drug Images
References/ Citation:
- Gonzalez, John P., and Julian M. Henwood. “Pefloxacin.” Drugs 37.5 (1989): 628-668.
- Montay, G., Y. Goueffon, and F. Roquet. “Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans.” Antimicrobial agents and chemotherapy 25.4 (1984): 463-472.
- Frydman, A. M., et al. “Pharmacokinetics of pefloxacin after repeated intravenous and oral administration (400 mg bid) in young healthy volunteers.” Journal of Antimicrobial Chemotherapy 17.suppl_B (1986): 65-79.